A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium

被引：0
|
作者：
Welch, S. [1 ,2 ,3 ,4 ,5 ]
Mackay, H. J. [1 ,2 ,3 ,4 ,5 ]
Hirte, H. [1 ,2 ,3 ,4 ,5 ]
Fleming, G. F. [1 ,2 ,3 ,4 ,5 ]
Morgan, R. [1 ,2 ,3 ,4 ,5 ]
Wang, L. [1 ,2 ,3 ,4 ,5 ]
Blattler, C. [1 ,2 ,3 ,4 ,5 ]
Ivy, S. P. [1 ,2 ,3 ,4 ,5 ]
Oza, A. M. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Princess Margaret Hosp, Phase II Consortium, Toronto, ON M4X 1K9, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Univ Chicago Consortium, Chicago, IL USA
[4] Calif Canc Consortium, Duarte, CA USA
[5] Natl Canc Inst, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5576
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia
    Correa, R.
    Mackay, H.
    Hirte, H. W.
    Morgan, R.
    Welch, S.
    Fleming, G. F.
    Wang, L.
    Blattier, C.
    Ivy, S. P.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Sridhar, Srikala S.
    Winquist, Eric
    Eisen, Andrea
    Hotte, Sebastien J.
    McWhirter, Elaine
    Tannock, Ian F.
    Mukherjee, Som D.
    Wang, Lisa
    Blattler, Chantale
    Wright, John J.
    Moore, Malcolm J.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1045 - 1049
  • [3] A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S. Sridhar
    Eric Winquist
    Andrea Eisen
    Sebastien J. Hotte
    Elaine McWhirter
    Ian F. Tannock
    Som D. Mukherjee
    Lisa Wang
    Chantale Blattler
    John J. Wright
    Malcolm J. Moore
    Investigational New Drugs, 2011, 29 : 1045 - 1049
  • [4] Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial or the PMH, Chicago, and California Phase II Consortia
    Wilson, Michelle
    Dhani, Neesha C.
    Hirte, Hai W.
    Welch, Stephen
    Steed, Helen
    Martin, Lalnie P.
    Lheureux, Stephanie
    Martin-Lorente, Cristina
    Mackay, Helen
    Butler, Marcus O.
    Wang, Lisa
    Quintos, Judy
    Allen, Katie
    Roman, Lynda
    Wright, John Joseph
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
    Castonguay, Vincent
    Lheureux, Stephanie
    Welch, Stephen
    Mackay, Helen J.
    Hirte, Hal
    Fleming, Gini
    Morgan, R.
    Wang, Lisa
    Blattler, Chantale
    Ivy, Percy S.
    Oza, Amit M.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 274 - 280
  • [6] A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
    Taylor, Sara K.
    Chia, Stephen
    Dent, Susan
    Clemons, Mark
    Agulnik, Mark
    Grenci, Pamela
    Wang, Lisa
    Oza, Amit M.
    Ivy, Percy
    Pritchard, Kathleen I.
    Leighl, Natasha B.
    ONCOLOGIST, 2010, 15 (08): : 810 - 818
  • [7] Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.
    Sridhar, SS
    Stadler, W
    Le, L
    Hedley, D
    Pond, G
    Wright, J
    Vokes, E
    Thomas, S
    Moore, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 422S - 422S
  • [8] A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Srikala S. Sridhar
    Mary J. Mackenzie
    Sebastien J. Hotte
    Som D. Mukherjee
    Ian F. Tannock
    Nevin Murray
    Christian Kollmannsberger
    Masoom A. Haider
    Eric X. Chen
    Robert Halford
    Lisa Wang
    S. Percy Ivy
    Malcolm J. Moore
    Investigational New Drugs, 2013, 31 : 1008 - 1015
  • [9] A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Sridhar, Srikala S.
    Mackenzie, Mary J.
    Hotte, Sebastien J.
    Mukherjee, Som D.
    Tannock, Ian F.
    Murray, Nevin
    Kollmannsberger, Christian
    Haider, Masoom A.
    Chen, Eric X.
    Halford, Robert
    Wang, Lisa
    Ivy, S. Percy
    Moore, Malcolm J.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 1008 - 1015
  • [10] Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
    Tang, P.
    Cohen, S. J.
    Bjarnason, G. A.
    Kollmannsberger, C.
    Virik, K.
    MacKenzie, M. J.
    Brown, J.
    Wang, L.
    Chen, A. P.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345